Restenosis and gene polymorphisms: All humans are equal, but some humans are more equal than others

Cardiology

Volumn 112, Issue 4, 2009, Pages 260-262

  Caixeta, Adriano ^a   Weisz, Giora ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL; RAPAMYCIN;

CELL PROLIFERATION; CHROMOSOME 9P; CLINICAL FEATURE; CORONARY ARTERY DISEASE; DNA POLYMORPHISM; DNA SEQUENCE; DRUG ELUTING STENT; GENE LOCUS; GENETIC ASSOCIATION; GENOME; GENOTYPE; HAPLOTYPE; HEART INFARCTION; HUMAN; MICROARRAY ANALYSIS; NOTE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RESTENOSIS; REVASCULARIZATION; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SMOOTH MUSCLE FIBER; STENT THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CHROMOSOMES, HUMAN, PAIR 9; CORONARY ARTERY DISEASE; GENETIC PREDISPOSITION TO DISEASE; GRAFT OCCLUSION, VASCULAR; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; STENTS;

EID: 50349103414     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000151694     Document Type: Note

References (21)

1. Farb A, Sangiorgi G, Carter AJ, Walley VM, Edwards WD, Schwartz RS, Virmani R: Pathology of acute and chronic coronary stenting in humans. Circulation 1999;99:44-52.
2. Hoffmann R, Mintz GS, Dussaillant GR, Popma JJ, Pichard AD, Satler LF, Kent KM, Griffin J, Leon MB: Patterns and mechanisms of in-stent restenosis: a serial intravascular ultrasound study. Circulation 1996;94:1247-1254.
3. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R: A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-1780.
4. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE: Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-1323.
5. Weisz G, Leon MB, Holmes DR Jr, Kereiakes DJ, Clark MR, Cohen BM, Ellis SG, Coleman P, Hill C, Shi C, Cutlip DE, Kuntz RE, Moses JW: Two-year outcomes after sirolimus-eluting stent implantation: results from the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trial. J Am Coll Cardiol 2006;47:1350-1355.
6. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME: A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-231.
7. Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Mahaffey KW, Cutlip DE, Fitzgerald PJ, Sood P, Su X, Lansky AJ: Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA 2008;299:1903-1913.
8. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, Colombo A, Schampaert E, Grube E, Kirtane AJ, Cutlip DE, Fahy M, Pocock SJ, Mehran R, Leon MB: Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007;356:998-1008.
9. Ashley EA, Ferrara R, King JY, Vailaya A, Kuchinsky A, He X, Byers B, Gerckens U, Oblin S, Tsalenko A, Soito A, Spin JM, Tabibiazar R, Connolly AJ, Simpson JB, Grube E, Quertermous T: Network analysis of human in-stent restenosis. Circulation 2006;114:2644-2654.
10. Christensen K, Murray JC: What genomewide association studies can do for medicine. N Engl J Med 2007;356:1094-1097.
11. Petretto E, Liu ET, Aitman TJ: A gene harvest revealing the archeology and complexity of human disease. Nat Genet 2007;39:1299-1301.
12. McPherson R, Pertsemlidis A, Kavaslar N, Stewart A, Roberts R, Cox DR, Hinds DA, Pennacchio LA, Tybjaerg-Hansen A, Folsom AR, Boerwinkle E, Hobbs HH, Cohen JC: A common allele on chromosome 9 associated with coronary heart disease. Science 2007;316:1488-1491.
13. Schunkert H, Gotz A, Braund P, McGinnis R, Tregouet DA, Mangino M, Linsel-Nitschke P, Cambien F, Hengstenberg C, Stark K, Blankenberg S, Tiret L, Ducimetiere P, Keniry A, Ghori MJ, Schreiber S, El Mokhtari NE, Hall AS, Dixon RJ, Goodall AH, Liptau H, Pollard H, Schwarz DF, Hothorn LA, Wichmann HE, Konig IR, Fischer M, Meisinger C, Ouwehand W, Deloukas P, Thompson JR, Erdmann J, Ziegler A, Samani NJ: Repeated replication and a prospective meta-analysis of the association between chromosome 9p21.3 and coronary artery disease. Circulation 2008;117:1675-1684.
14. Monraats PS, Kurreeman FA, Pons D, Sewgobind VD, de Vries FR, Zwinderman AH, de Maat MP, Doevendans PA, de Winter RJ, Tio RA, Waltenberger J, Huizinga TW, Eefting D, Quax PH, Frants RR, van der Laarse A, van der Wall EE, Jukema JW: Interleukin 10: a new risk marker for the development of restenosis after percutaneous coronary intervention. Genes Immun 2007;8:44-50.
15. Manolis AS, Patsouras N, Ilias I, Constantakopoulos J, Pyriohou A, Lymperopoulos A, Spathas DH, Flordellis CS: Lack of association between alpha2B-adrenergic receptor polymorphism and risk of restenosis following coronary angioplasty and stent implantation - preliminary report. Clin Chem Lab Med 2006;44:807-812.
16. Oguri M, Kato K, Hibino T, Yokoi K, Segawa T, Matsuo H, Watanabe S, Nozawa Y, Murohara T, Yamada Y: Genetic risk for restenosis after coronary stenting. Atherosclerosis 2007;194:e172-e178.
17. Gross CM, Perrot A, Geier C, Posch MG, Hassfeld S, Kramer J, Schmidt S, Derer W, Dietz R, Ozcelik C: Recurrent in-stent restenosis is not associated with the angiotensin-converting enzyme D/I, angiotensinogen Thr174Met and Met235Thr, and the angiotensin-II receptor 1 A1166C polymorphism. J Invasive Cardiol 2007;19:261-264.
18. Pons D, Monraats PS, de Maat MP, Pires NM, Quax PH, van Vlijmen BJ, Rosendaal FR, Zwinderman AH, Doevendans PA, Waltenberger J, de Winter RJ, Tio RA, Frants RR, van der Laarse A, van der Wall EE, Jukema JW: The influence of established genetic variation in the haemostatic system on clinical restenosis after percutaneous coronary interventions. Thromb Haemost 2007;98:1323-1328.
19. Shah SH, Hauser ER, Crosslin D, Wang L, Haynes C, Connelly J, Nelson S, Johnson J, Gadson S, Nelson CL, Seo D, Gregory S, Kraus WE, Granger CB, Goldschmidt-Clermont P, Newby LK: ALOX5AP variants are associated with in-stent restenosis after percutaneous coronary intervention. Atherosclerosis 2008, E-pub ahead of print.
20. Jorgensen E, Kelbaek H, Helqvist S, Jensen GV, Saunamaki K, Kastrup J, Havndrup O, Bundgaard H, Kyst Madsen J, Christiansen M, Andersen PS, Reiber JH: Predictors of coronary in-stent restenosis: importance of angiotensin-converting enzyme gene polymorphism and treatment with angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2001;38:1434-1439.
21. Tiroch K, Koch W, Mehilli J, Böttiger C, Schömig A, Kastrati A: P27 and P53 gene polymorphisms and restenosis following coronary implantation of drug-eluting stents. Cardiology 2009;112:263-269.